KIF17

Across TCGA pan-cancer cohorts, KIF17 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KIF17 data layer compared with 17 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KIF17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIF17 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, UCEC, and GBM are the cancer types where KIF17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.167	0.604	.006	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →
LIHC	DFS	Median	All	0.096	0.526	.023	3	view →
LUSC	OS	Median	III,IV	0.178	0.663	.044	3	view →
LUAD	DFS	Median	All	1.000	0.785	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KIF17–HNSC (DFS)

Open the HNSC breakdown →